Professor Creswell Eastman AO is a world-renowned endocrinologist with a primary interest in Iodine Deficiency Disorders. He is the Clinical Professor of Medicine at the University of Sydney School of Medicine and Consultant Emeritus to Westmead Hospital.
Professor Eastman recently spoke to Australian Health Journal about iodine deficiency in pregnancy preparation and the mother’s health during pregnancy. May is the time of the year for the Australian Thyroid Foundation’s (ATF) Thyroid Awareness Month and Professor Eastman spoke about why iodine deficiency has become an even greater risk in Australians in recent years. He stresses the importance of public health literacy and health care professionals (HCPs) having a better understanding of the disorders associated with iodine deficiency.
Recent research from The Lancet – March 2022 emphasises the consequences and risks of an inadequate amount of thyroid hormone at conception, during pregnancy and whilst breastfeeding.
‘Without an adequate amount of thyroid hormone mothers can be exposed to hypertensive disorders of pregnancy, including gestational hypertension and preeclampsia or eclampsia, which affect around 10% of pregnant women and are the leading causes of maternal and neonatal mortality worldwide. Mothers who suffer from hypertensive disorders during pregnancy are at increased risk of long-term cardiovascular consequences and hypertensive disorders in subsequent pregnancies. Evidence also indicates a risk of reduced cognitive ability to their offspring.
‘Knowing if you are genetically predisposed to Hashimoto’s or Graves’ Diseases, which are both thyroid autoimmune disorders is important to be aware of, to ensure all appropriate tests are ordered. Autoimmune disorders may predispose mothers to a thyroid problem during pregnancy’, says Professor Creswell Eastman, who also serves as the ATF’s Principal Medical Advisor.
‘Unnecessary risks to a pregnancy and the mother’s health during pregnancy and ongoing is something that can be avoided and prevented. Raising awareness and ensuring thyroid tests are ordered by GP’s, when couples are planning a family and when the pregnancy is confirmed are both essential.
-
Research funded to investigate early-onset bowel cancer progression
Bowel Cancer Australia recently announced a team led by Professor Michael Samuel as the successful applicant for a three-year $600k early-onset bowel cancer research project through the 2023 round of Cancer Australia’s Priority-driven Collaborative Cancer Research Scheme (PdCCRS).
-
ARCS Annual Conference 2019
Earlier this month, ARCS Australia held it’s Annual Conference at the International Convention Centre Sydney – ICC Sydney, with the theme of putting patients at the centre of healthcare. Uniquely, the conference included a number of patients who attended, presented or were referenced.
-
Medicinal cannabis in Australia Update
According to the Australian Journal of General Practice, published by the Royal Australian College of General Practitioners, more than 130,000 medicinal cannabis approvals have been issued in Australia to date, mostly by general practitioners, with approximately 65% of these to treat chronic non-cancer pain. Despite robust supportive data from animal models, current clinical trial evidence for THC and CBD efficacy in chronic pain is incomplete. In their prescribing decisions, doctors must balance patient demand and curiosity with caution regarding potential risks and limited efficacy (Source: https://www1.racgp.org.au/ajgp/2021/october/medicinal-cannabis)
Australian Health Journal met with 3 speakers at the recent @arcsaustralia ARCS22 Conference providing an update on medicinal cannabis. The discussion with the speakers now centres on affordability and access.
